| |
著者: Kiyoto Shiga, Ken-Ichi Nibu, Yasushi Fujimoto, Takahiro Asakage, Akihiro Homma, Hiroki Mitani, Takenori Ogawa, Kenji Okami, Shigeyuki Murono, Shigeru Hirano, Tsutomu Ueda, Nobuhiro Hanai, Kiyoaki Tsukahara, Ichiro Ota, Seiichi Yoshimoto, Takeshi Shinozaki, Shigemichi Iwae, Katsunori Katagiri, Daisuke Saito, Naomi Kiyota, Makoto Tahara, Fumiaki Takahashi, Ryuichi Hayashi
雑誌名: Laryngoscope. 2021 Mar;131(3):E870-E874. doi: 10.1002/lary.28936. Epub 2020 Jul 30.
Abstract/Text
OBJECTIVES: This study aimed to evaluate the efficacy of chemoradiotherapy (CRT) for patients with advanced cancer of the external auditory canal (EAC) by analyzing the outcome of the patients.
METHODS: This is a multi-institutional retrospective survey, and we reviewed the medical records of the subjects. A total of 181 patients with tumor (T)3 or T4 tumor in 17 institutions were enrolled. Further analysis was performed for 74 patients who underwent CRT under curative intent.
RESULTS: Overall 5-year survival rates of the patients who underwent CRT (n = 74) were 54.6%. Those of the patients who underwent CRT with modified TPF (docetaxel, cisplatin [CDDP], and 5-fluorouracil) regimen (n = 50) and CRT with CDDP regimens (n = 24) were 64.4% and 36.7%, respectively. Significant differences were observed between these two groups.
CONCLUSION: Given the tendency that head and neck surgeons prefer CRT for advanced larger cancer of the EAC, CRT for advanced EAC cancer using the modified TPF regimen showed good clinical outcomes.
LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E870-E874, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.
PMID 33216374 Laryngoscope. 2021 Mar;131(3):E870-E874. doi: 10.1002/lary.28936. Epub 2020 Jul 30.
|
